Science
ADEL-Y01 Phase 1a/1b trial reports no adverse events Sanofi to lead further development

Oscotec received the clinical study report for the Phase 1a/1b trial of ADEL-Y01, a candidate treatment for Alzheimer’s disease. Safety and tolerability were confirmed in healthy participants who received a single intravenous dose of up to 100 mg/kg.
Oscotec disclosed on the 4th through the electronic disclosure system that it had received the clinical study report (CSR) for the Phase 1a/1b trial of ADEL-Y01 from the contract research organization (CRO). The trial was conducted with approval from the U.S. Food and Drug Administration (FDA).
The trial was designed to evaluate the safety and tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of intravenous ADEL-Y01 in patients with mild cognitive impairment (MCI) due to Alzheimer’s disease or mild Alzheimer’s disease, as well as in healthy participants.
The trial was randomized and double-blind, and consisted of a Phase 1a single ascending dose (SAD) study and a Phase 1b multiple ascending dose (MAD) study. It was conducted at five hospitals in the United States and lasted 35 months.
The results showed no treatment-emergent adverse events (TEAEs) related to the study drug, serious adverse events (SAEs) or discontinuations due to adverse events. No antidrug antibodies (ADAs) were observed.
However, only 42 participants were enrolled, compared with the original target of 73. This was because the existing trial was terminated for business reasons during the transition of development responsibilities after ADEL-Y01 was licensed to Sanofi on Dec. 16 last year.
Oscotec said Sanofi is expected to conduct further clinical development of ADEL-Y01. The company cautioned investors, noting that the statistical probability of a clinical trial drug ultimately receiving marketing approval is about 10%.

BIOBOOK TEAM
biobookmedia@biobook.co.kr
Novartis’ Cosentyx approved for 11th indication, becoming first treatment for polymyalgia rheumatica

Oral IL-23-targeting psoriasis drug icotrokinra approved in Brazil; one tablet daily

Aribio’s Oral Alzheimer’s Drug Meets Trial Goal in Monotherapy Group, Slowing Progression by 31%

SELLAS Leukemia Vaccine Extends Survival by 9 Months, Meets Phase 3 Endpoint

Korean Drugmakers Race to Develop Obesity Treatments That Preserve Muscle During Weight Loss

Growth pathway identified in ‘difficult-to-treat’ triple-negative breast cancer, raising potential to repurpose existing drugs